Clinical Trial Scheme of Tanreqing Capsules in the Treatment of COVID-19
Status:
Not yet recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This study was conducted in a randomized, double-blind, placebo-controlled, multicenter
clinical trial design. Two groups were designed, the experimental group and the placebo
control group. Patients in both groups received basic treatment with vitamin C effervescent
tablets. Tanreqing capsule was added to basic treatment in the experimental group, and
placebo was added to basic treatment in the control group. The treatment course was 7 days,
and the observation period was set to 7 days, with a daily visit.